MAY 30, 2018 5:42 AM PDT

Blood Vessel Growth Promoting Factor May Treat Osteoporosis

WRITTEN BY: Nouran Amin

According to a new study at Weill Cornell Medicine, a blood vessel growth promoting-molecule may create a suitable environment for bone-building, providing hope for potential new drugs in the treatment of osteoporosis and fractures.

These research findings were published May 21 in the journal Nature Medicine and provided evidence of a substance involved in the development of nerve growth, known as SLIT3, was seen to reverse the bone-weakening effects of osteoporosis and aided in the healing of fractures in mouse models. This multi-center research effort could inspire drug development efforts that target the SLIT3 pathway in humans, allowing for a new approach in blood vessel-directed therapy in the treatment of bone loss, persistent fractures, and fragile bones.

As of now, existing drugs for osteoporosis work in one of two ways: (1) inhibit the cellular processes that destroy bone or (2) promote bone formation by activating osteoblasts. “But only those promoting new bone formation will help you actually heal a bone fracture,” says co-senior study author Dr. Matthew Greenblatt, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine. “Our findings have potentially demonstrated a third category: drugs that target blood vessel formation within bone, prompting new bone to form.”

Osteoporosis, a disease that leads to bone thinning and bone brittleness, causes nearly 9 million fractures worldwide annually, or one every three seconds, according to the International Osteoporosis Foundation. Women are more likely to be affected with osteoporosis and their risk significantly increases with age. One in two women and one in five men will have at least one osteoporotic fracture in their lifetimes, unfortunately, these fractures kill as many women as breast cancer. “Osteoporosis and skeletal fractures due to osteoporosis are both common and deadly,” Greenblatt said.

Investigators found that osteoblasts secreted unchanged amounts of almost all blood vessel growth-promoting factors. However, SLIT3 levels were higher than the rest of the factors in significant amounts; and when the mouse models were genetically modified to delete the expression of SLIT3, they immediately developed low bone mass.

“We next asked if we could use SLIT3 to treat mice with skeletal disease, especially osteoporosis and fracture healing,” Dr. Greenblatt said. “When we gave the rodents SLIT3, it reversed their osteoporosis and made their fractures heal faster and stronger. “To my knowledge, this is the first example that we can develop a drug to treat bone disease in mice not by targeting the bone-forming cells,” he said, “but instead by targeting special types of blood vessels that exist in bone.”

Source: Cornell Chronicle. HGH therapy for osteoporosis

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 25, 2020
Drug Discovery & Development
Drug Combination Reduces Cardiovascular Complications
AUG 25, 2020
Drug Combination Reduces Cardiovascular Complications
According to a new study, combining the drugs hydroxychloroquine (HCQ) and azithromycin (AZM) was shown to reduce cardio ...
AUG 29, 2020
Drug Discovery & Development
MDMA and LSD Combo to Enter Clinical Trials
AUG 29, 2020
MDMA and LSD Combo to Enter Clinical Trials
Scientists from the pharmaceutical company, MindMed, have announced the beginning of Phase 1 clinical trials to test Sch ...
SEP 10, 2020
Drug Discovery & Development
Common Painkiller Increases Risk-Taking Behavior
SEP 10, 2020
Common Painkiller Increases Risk-Taking Behavior
Researchers from Ohio State University have found that the common painkiller, paracetamol ( also known as Tylenol and Pa ...
SEP 22, 2020
Drug Discovery & Development
New Treatment for Mouth-Hand-Foot Disease
SEP 22, 2020
New Treatment for Mouth-Hand-Foot Disease
A study appearing next week in the journal Nature Communications offers some good news in the search for antiviral drugs ...
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
OCT 22, 2020
Neuroscience
Psychedelic Experiences Reduce Narcissistic Personality Traits
OCT 22, 2020
Psychedelic Experiences Reduce Narcissistic Personality Traits
Researchers from the UK have found that psychedelic drugs can positively affect narcissistic personality traits- by redu ...
Loading Comments...